

STATUS OF THE CLAIMS

Claims 1-10 (cancelled)

11. (Amended) A method for ~~screening~~ determining whether an agent will which inhibit an angiogenic response comprising

a) contacting:

i) an inactive pro form or convertase-activated form of an integrin α subunit involved in angiogenesis,

ii) an agent to be tested for the ability to inhibit angiogenesis, and

iii) metalloprotease MT1-MMP,

under conditions promoting an increase in activation of the integrin α subunit in the absence of said agent, and

b) correlating inhibition of said increase in integrin α subunit activation with the ability of the agent to inhibit angiogenesis.

12. (Amended) The method of claim 11 wherein the correlating step is accomplished by observing a difference in migration of the activated form versus the inactive form of the α ~~alpha~~ subunit in electrophoresis or chromatography.

13. (Previously added) The method of claim 11 wherein the MT1-MMP and pro form of the integrin α subunit are recombinantly expressed within the same cell.

14. (Previously added) The method of claim 11 in which said contacting step is performed within a cell.

15. (Amended) The method of claim 11 in which the activation of said α ~~alpha~~ subunit is accomplished by cleavage of the pro form of said α ~~alpha~~ subunit.

16. (Amended) The method of claim 11 wherein the activation of said α ~~alpha~~ subunit is accompanied by a change in glycosylation of the pro form of said α ~~alpha~~ subunit.
17. (Amended) The method of any one of the foregoing claims in which the α ~~alpha~~ subunit comprises the α_v subunit.